Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$44.95K$44.95K+544.8% vs Q1 2018 Net Income-$2.41M-$2.41MN/M vs Q1 2018 EPS Diluted-$4.99-$4.99— vs Q1 2018 Gross Profit$37,241+434.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$528,233N/M Margins · derivedGross margin82.8%−17.2 pt vs Q1 2018
Operating margin-1808.6%+16483.8 pt vs Q1 2018
Net margin-5352.9%+3524.3 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end